PBIO vs. PRPO, TLIS, SQL, RPID, BLI, AEZS, NSPR, CLRB, PCHM, and UPC
Should you be buying Pressure BioSciences stock or one of its competitors? The main competitors of Pressure BioSciences include Precipio (PRPO), Talis Biomedical (TLIS), SeqLL (SQL), Rapid Micro Biosystems (RPID), Berkeley Lights (BLI), Aeterna Zentaris (AEZS), InspireMD (NSPR), Cellectar Biosciences (CLRB), PharmChem (PCHM), and Universe Pharmaceuticals (UPC). These companies are all part of the "medical" sector.
Pressure BioSciences vs.
Pressure BioSciences (OTCMKTS:PBIO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Precipio has a net margin of -108.80% compared to Pressure BioSciences' net margin of -939.40%. Pressure BioSciences' return on equity of 0.00% beat Precipio's return on equity.
Precipio received 190 more outperform votes than Pressure BioSciences when rated by MarketBeat users. Likewise, 73.51% of users gave Precipio an outperform vote while only 61.65% of users gave Pressure BioSciences an outperform vote.
Precipio has higher revenue and earnings than Pressure BioSciences.
Pressure BioSciences has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Precipio has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.
In the previous week, Precipio had 1 more articles in the media than Pressure BioSciences. MarketBeat recorded 2 mentions for Precipio and 1 mentions for Pressure BioSciences. Precipio's average media sentiment score of 0.44 beat Pressure BioSciences' score of -0.75 indicating that Precipio is being referred to more favorably in the news media.
0.1% of Pressure BioSciences shares are owned by institutional investors. Comparatively, 9.6% of Precipio shares are owned by institutional investors. 14.6% of Pressure BioSciences shares are owned by company insiders. Comparatively, 10.6% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Precipio has a consensus target price of $2.85, indicating a potential upside of 367.98%. Given Precipio's higher possible upside, analysts clearly believe Precipio is more favorable than Pressure BioSciences.
Summary
Precipio beats Pressure BioSciences on 11 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Pressure BioSciences Competitors List
Related Companies and Tools